Paper: High-Dose Methotrexate Is Not Associated with Reduction in CNS Relapse in Patients with Aggressive B-Cell Lymphoma: An International Retrospective Study of 2300 High-Risk Patients
retrospective review of 2300 high risk DLBCL patients (CNS IPI 4-6) high-dose methotrexate was not associated with a decreased rate of CNS relapse. CNS relapse rate was ~9% in the total cohort and 5-6% in the cohort of patients who achieved a CR. CNS IPI again predicted patients at high risk for CNS relapse, but unfortunately it does not appear that our current prophylactic approaches are effective.
